Nasal Decongestion and Obstructive Sleep Apnea
- Registration Number
- NCT00630474
- Lead Sponsor
- University of Zurich
- Brief Summary
Whether impaired nasal breathing contributes to sleep related breathing disturbances has not been known. Therefore, the purpose of the study is to compare the effect of xylometazoline, a drug that decongests the nasal mucosa when applied locally, with placebo in terms of sleep and nocturnal breathing and daytime performance.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
- Obstructive sleep apnea syndrome (excessive sleepiness, apnea/hypopnea index >10/h)
- Chronic nasal congestion (complaint of impaired nasal breathing that interfered with subjective sleep quality on at least 3 nights per week during at least the last 3 months)
Exclusion Criteria
- Nasal surgery within the last 6 months
- Current treatment with nasal decongestants or topical steroids
- Sleep disorders other than obstructive sleep apnea
- Internal medical or psychiatric disorders that interfered with sleep
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description 1 xylometazoline nasal application of xylometazoline 2 xylometazoline nasal application of placebo
- Primary Outcome Measures
Name Time Method sleep related breathing disturbances sleep efficiency daytime sleepiness at end of one week treatment
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Pulmonary Division, University Hospital Zurich
🇨ðŸ‡Zurich, Switzerland
Pulmonary Division, University Hospital Zurich, Switzerland
🇨ðŸ‡Zurich, Switzerland